RE:RE:RE:RE:89 bio The cost of trials increases from phase to phase so does the probability of success. A phase 2 trial costs less than phase 3 but is valued less too. The commercial risks for phase 3 is less than phase 2 etc etc.
As many said many times this is a business decision for a company with limited resources, the reason market reacted to the news or better said didn't reacted to the news is the issue which has to be addressed, yes this is an asset which should be valued in the SP.
Not to ascribe any value to it in today's market when many R&D companies get fairly or unfairly valued based on future potentials is just not right. The potential of the protocol is there now than it's finalized it needs to be marketed. They couldn't or wouldn't talk about it publicly as per ongoing negotiations now they can and should.